Table 3.
Factors associated with overall survival in 87 patients with hepatocellular carcinoma
| Character | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
|
|
|
||||
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age (year) | 0.998 (0.970-1.026) | .872 | |||
| Sex | Female vs male | 2.163 (0.659-7.105) | .203 | ||
| Alcohol | No vs yes | 1.347 (0.710-2.556) | .362 | ||
| HBV | No vs yes | 0.614 (0.342-1.105) | .104 | ||
| HCV | No vs yes | 1.053 (0.533-2.081) | .882 | ||
| Grade 1-2 irAEs | Yes vs no | 2.419 (1.157-5.055) | .019 | 2.217 (1.005-4.892) | .049 |
| Grade ≥3 irAEs | Yes vs no | 1.290 (0.573-2.905) | .539 | ||
| TTV (cm3) | ≤1000 vs >1000 | 3.511 (1.858-6.633) | <.001 | ||
| Tumor number | Single vs multiple | 3.144 (1.234-8.012) | .016 | ||
| MVI | No vs yes | 2.806 (1.443-5.458) | .002 | ||
| EHM | No vs yes | 1.614 (0.855-3.049) | .140 | ||
| CLIP score | 0-2 vs ≥3 | 6.146 (3.042-12.418) | <.001 | 3.717 (1.537-8.988) | .004 |
| AFP (ng/mL) | <400 vs ≥400 | 1.605 (0.878-2.935) | .124 | ||
| NLR | ≤3.0 vs >3.0 | 14.533 (1.993-105.976) | .008 | ||
| AST (U/L) | ≤40 vs >40 | 1.633 (0.687-3.885) | .267 | ||
| ALT (U/L) | ≤40 vs >40 | 2.080 (1.086-3.985) | .027 | ||
| Child-Pugh class | A vs B/C | 2.886 (1.556-5.355) | .001 | ||
| ALBI grade | 1 vs 2/3 | 4.202 (1.492-11.840) | .007 | ||
| Prior therapy | |||||
| Sorafenib | No vs yes | 0.852 (0.475-1.528) | .591 | ||
| Lenvatinib | No vs yes | 1.170 (0.491-2.788) | .723 | ||
| Concurrent therapy | No vs yes | 0.399 (0.222-0.716) | .002 | ||
| TKI | No vs yes | 0.635 (0.353-1.143) | .130 | ||
| TACE | No vs yes | 0.197 (0.047-0.818) | .025 | ||
| RT | No vs yes | 1.383 (0.543-3.518) | .496 | ||
| AFP response | Yes vs No | 1.872 (0.880-3.796) | .106 | ||
| Best response | CR + PR vs none | 4.935 (1.749-13.920) | .003 | ||
AFP, α-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CLIP, Cancer of the Liver Italian Program; CR + PR, complete response plus partial response; EHM, extrahepatic metastasis; HBV, hepatitis B virus; HCV, hepatitis C virus; irAEs, immune-related adverse events; MVI, macroscopic vascular invasion; NLR, neutrophil-lymphocyte ratio; RT, radiotherapy; TACE, transarterial chemoembolization; TKI, tyrosine kinase inhibitor; TTV, total tumor volume.